Clinical Trials Highlights
New and notable cancer research studies by some of Sylvester’s top investigators.
Heat Shock Protein Vaccine for Brain Cancer
Investigator: Ricardo J. Komotar, M.D.
Sylvester Comprehensive Cancer Center is conducting a Phase II clinical trial open to qualified brain cancer patients with glioblastoma multiforme.
The trial targets the immune system and activates a patient specific T-cell response using heat shock protein vaccine HSPPC-96.
The trial consists of two main steps. First, surgeons remove the malignant tumor and isolate essential proteins from it. Six to eight weeks later, they inject those proteins into the patient’s arm. The patient’s immune system recognizes these proteins as invaders, and produces billions of T-cells, its natural attack system, to fight it, without injury to normal neural and glial structures.
To qualify for this trial, the patient must not have received chemotherapy or radiation, and have sufficient tumor to produce the vaccine. Three eligible scenarios exist:
- The patient is diagnosed by MRI with glioblastoma multiforme and has tumor removal/vaccine production at the University of Miami Hospital and Clinics.
- The patient already had the diagnosis of glioblastoma multiforme by biopsy and undergoes tumor removal/vaccine production at the University of Miami Hospital and Clinics.
- The patient already had partial resection of their glioblastoma multiforme and undergoes complete tumor removal/vaccine production at the University of Miami Hospital and Clinics.
The preliminary results have been promising, and no serious side effects have been reported to date. Sylvester is one of only 10 medical centers in the country offering this treatment, and the only one in Florida.